Bavarian Nordic — September 2017
-
Bava: Lad os se lidt nærmere på hvad vi kan se ind i af økonomi vedrørende Prostvac i den kommende tid:
http://www.bullfax.com/?q=node-bristol-myers-squibb-co-bmy-signs-exclusive-prostate-ca -
Under the deal, Bavarian Nordic will be entitled to an upfront payment of $60 million and will be receiving $975 million overall if specific targets are met and milestones achieved. These milestones would include a payment of $80 million when Bristol-Myers exercises the option to license the drug, which it can do only within a specific time period after the final results from the ongoing Phase III trial are revealed. Bavarian Nordic will then receive incremental payments beginning from $50
-
million and reaching more than $230 million if Prostvac is able to show a higher overall survival benefit in Phase III results. Additionally, Bavarian Nordic would also be entitled to $110 million as part of the regulatory milestone payment, while receiving as much as $496 million in achieving the sales targets.
-
Om alt går vel ligger Bavarian altså i en position vedrørende Prostvac med kommende salgsroyalty's og salgsmilestones på optil 500 mio USD (hvilket jo en september dag virker som fugle på taget) - men hvor vi altså på KORT sigt kan se ind i milestonebetalinger på mellem 130 mio USD (80+50) til 280 mio USD (50+230).
-
Er der en som kan lidt mere ud af dette her end jeg: http://www.healingwell.com/community/default.aspx?f=35&m=3900747
-
Koppeaftale med USA. I udbudsmaterialet stor der en udbudssum omkring 100 mio. dollar. Jeg har set at Paul Chaplin forventer en aftale på minimum 1 mia. dollar. Hvordan hænger det sammen
-
Kurt: nu kender vi jo ikke hans tidshorisont, men Sydbank anslår det til 470 mio usd over 3-4 år, idet man forhåbentligt i US ønsker aterstatte de esisterende 20 mio. doser i den nuværende flydende-frosne version af IMVAMUNE til frysetørrede doser - linkhttps://markets.sydbank.dk/PublicationsWebHandler/Sydbank.aspx?ID=0036696-048556
-
Interview Archives
Stay informed about the latest trends and developments with captivating interviews with key figures in the biotech industry.
Labiotech.eu (labiotech.eu)
-
-
33,9 måneder samlet - det er vel fint
-
Disse data ser meget fine ud, med mindre placebo-gruppen denne gang har performet væsentlig bedre end ved tidligere studier.
-
Og det kan man desværre ikke udelukke. Men er det sandsynligt?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind